Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.
Gain Therapeutics cleared to start study of GT-02287 in Australia
Complement Therapeutics Begins i-GAIN Study
Gain Therapeutics - Force Family Office
Natália Pérez-Carmona - Director, Biology at Gain Therapeutics
Terenzio Ignoni - SVP, Quality & CMC at Gain Therapeutics
Gain Therapeutics' collaboration with Zentalis Pharmaceuticals so
Doubling Down On Gain Therapeutics (NASDAQ:GANX)
INTEGRA Investor Outreach
Matthias Alder - CEO at Gain Therapeutics
Gain Therapeutics Touts Additional Encouraging Preclinical Data
Gain Therapeutics Presents New Preclinical Data of Drug Candidate
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data